OIS Podcast | Ophthalmology's leading Podcast

Alphaeon is tapping physicians for unprecedented involvement in finding and funding new treatments. Hear how the company sees the future of health care. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorsh...

With just two weeks away from OIS@ASCRS, Conference Co-Chair Bill Link, managing director of Versant Ventures, reviews the highlights of the upcoming meeting includ-ing a tight focus on glaucoma and plenary talk by J. Michael Pearson of Valeant.

Description: Laurent Attias, Alcon’s head of business development and licensing, shares the company’s overall view on where promising innovation should originate.

ASCRS Program Chair Ed Holland Talks ASCRS Meeting, Technology and Oph-thalmology: The Next Generation. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Companies Any other questions? Cont...

Seattle Ophthalmologist Audrey Talley Rostov explains how she became involved in an international movement to end corneal blindness. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Compan...

Mark Blumenkranz, MD, has had a hand in starting many exciting biotech, medtechs and digital health companies. Hear how his innovative process begins and what he’s doing to help foster new ideas in ophthalmology. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who ar...

Alcon’s Warner, Frinzi Discuss the WaveTec Vision Acquisition Details The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Companies Any other questions? Contact the producer of OIS, Craig Sim...

Description: Ophthalmology Industry Veteran Russ Trenary Reveals How InnFocus Intends to Capture a Piece of the Growing MIGs Market. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Compan...

Jon Norris, Managing Director of Health Care at Silicon Valley Bank, gives a sneak peak on his coming report on the health care sector and discusses why ophthalmology continues to be a strong source of innovation. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who a...

DigiSight President and CEO Doug Foster explains how mobile technologies like his company’s SightBook app can help save patient vision and help the pharmaceutical industry develop new ophthalmology drugs. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are drivin...

Vance Thompson, MD, sees patient “Experience” as a secret weapon in building a successful practice. He shares the steps his group takes to ensure patient service is as big a draw as new technologies. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving oph...

The ophthalmology patient base often is seen as a single, monolithic mass. But different generations have different needs and must be approached appropriately, says Dr. George O. Waring IV. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic in...

Second Sight President & CEO Robert Greenberg, MD, PhD looks back on Sec-ond Sight’s long road to getting FDA approval for Argus II and considers the path not taken.

Eleven Biotherapeutics capitalized on exciting technology and promising clinical results for its lead Dry Eye product to stage a successful IPO in 2014. Abbie C. Celniker, PhD, President and CEO, talks frankly about her leadership style, dealing with public investors, and how she’s man-aging high expectations for lead product EBI-005.

OIS co-chair Cunningham delivers a high altitude review of the much sought after "Year in Review" report he delivers at each event. In this review, Cunningham touched upon his hopes for the sector and OIS.

TearScience CEO Tim Willis discusses the emergence of Dry Eye Disease and details how his company’s diagnostic and treatment for a source of the condition could help meet the increasing interest from physicians and patients.

The FDA turned away Alimera Sciences’ bid to market Iluvien as a treatment for diabetic macular edema three times before finally giving the green light. President & CEO Dan Myers shares what kept his confidence up during this lengthy review and how Alimera Sciences is positioning Iluvien in the DME market.

OIS stalwart Jack Holladay, MD shares details on the work of a task force com-prised of representatives from the American Academy of Ophthalmology and the Food and Drug Administration charged with updating the regulatory agency’s Grid and developing a Guidance Document for Extended Depth of Focus and Accommodating IOLs. The Guidelines should help foster a new age of lenses by enabling lens makers...

Prior to starting Ocular Therapeutix, Amar Sawhney, already a successful medtech entrepreneur was a bit concerned about the unique challenges posed by the ophthal-mology sector. Today, with the commercial launch of its ReSure Sealant underway and a suc-cessful IPO completed, Sawhney says he’s more than confident in the plan to build OCUL into a significant ophthalmic player.

Jeff George, President & Global Head of Alcon, shares his optimism for the oph-thalmology sector with attendees at the recent Ophthalmology Innovation Summit in Chicago. George explained what opportunities Alcon was putting research and development dollars to-wards (spoiler, one involves Google.) He also identified what he saw as intriguing companies and technologies outside of Alcon.

At the recent Ophthalmology Innovation Summit in Chicago, Jeff George, Presi-dent & Global Head of Alcon; David E.I. Pyott, CEO of Allergan; Murthy V. Simhambhatla, PhD, President of Abbott Medical Optics; and Ashley McEvoy, Company Group Chairman of Johnson & Johnson Vision Care shared how they balance external innovation with the acquisition of out-side technologies to further the ophtha...

At the recent Ophthalmology Innovation Summit in Chicago, Google and Alcon executives shared the origins and potential outcomes of the partnership between the two com-panies. Initially, they hope to develop a contact lens capable of measuring the wearer’s glucose levels but future applications are even bolder.

Dorit B. Donoviel, PhD, Deputy Chief Scientist and Industry Forum Lead of the National Space Biomedical Research Institute, and Randy McDonald, Founder and President of the Magnum Group, discuss a new program created to address ocular disorders associated with space trav-el. In a partnership between government and the ophthalmology industry, a team of clinicians, entrepreneurs and investors will p...

As Global Head of Development Franchise Ophthalmics at Novartis, Dirk Sauer has overseen the development of Novartis’ blockbuster Lucentis. Now, his focus is on the pharmaceutical gi-ant’s pipeline of retina compounds, including many in the early stages. Hear how Sauer views innovation, both inside and outside of Novartis.

Gobiquity CEO Michael Brownell breaks down the mobile ophthalmology market from the viewpoint of a start-up that’s set to change how kids are diagnosed with amblyopia, the number one cause of vision loss in kids.